CYP1A2 genetic polymorphisms are associated with treatment response to the antidepressant paroxetine

Pharmacogenomics

Volumn 11, Issue 11, 2010, Pages 1535-1543

  Lin, Keh Ming ^a   Tsou, Hsiao Hui ^a   Tsai, I Ju ^a   Hsiao, Mei Chun ^b   Hsiao, Chin Fu ^a   Liu, Chia Yih ^b   Shen, Winston W ^c   Tang, Hwa Sheng ^d   Fang, Chun Kai ^e   Wu, Chi Shin ^f   Lu, Shao Chun ^g   Kuo, Hsiang Wei ^a   Liu, Shu Chih ^a   Chan, Hsiu Wen ^a   Hsu, Ya Ting ^a   Tian, Jia Ni ^a   Liu, Yu Li ^a  

^a NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^b CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^c TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^d TAIPEI CITY HOSPITAL   (Taiwan)

^e MACKAY MEMORIAL HOSPITAL   (Taiwan)

^f FAR EASTERN MEMORIAL HOSPITAL   (Taiwan)

^g NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

CYP1A2; depression; HAM A n HAM D; paroxetine; SNP

Indexed keywords

CYTOCHROME P450 1A2; IMIPRAMINE; LORAZEPAM; PAROXETINE; ZOLPIDEM;

ADULT; ANXIETY DISORDER; ARTICLE; BLOOD SAMPLING; CHINESE; CONTROLLED STUDY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG RESPONSE; ETHNICITY; EVENING DOSAGE; FEMALE; GENE FREQUENCY; GENE LINKAGE DISEQUILIBRIUM; GENE LOCUS; GENETIC POLYMORPHISM; GENOTYPE; HAMILTON ANXIETY SCALE; HAMILTON SCALE; HAPLOTYPE; HAPLOTYPE MAP; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; ONSET AGE; PROTEIN FUNCTION; SINGLE NUCLEOTIDE POLYMORPHISM; STEADY STATE;

ADULT; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; COHORT STUDIES; CYTOCHROME P-450 CYP1A2; DEPRESSIVE DISORDER, MAJOR; FEMALE; HUMANS; MALE; PAROXETINE; POLYMORPHISM, SINGLE NUCLEOTIDE; TREATMENT OUTCOME;

EID: 78649706451     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.10.128     Document Type: Article

References (40)

1. Sjoholm L, Lavebratt C, Forsell Y: A multifactorial developmental model for the etiology of major depression in a population-based sample. J. Affect. Disord. 113, 66-76 (2009).
2. Suija K, Kalda R, Maaroos HI: Patients with depressive disorder, their co-morbidity, visiting rate and disability in relation to self-evaluation of physical and mental health: a cross-sectional study in family practice. BMC Fam. Pract. 10, 38 (2009).
3. Chien I, Kuo C, Bih S et al.: The prevalence and incidence of treated major depressive disorder among National Health Insurance enrollees in Taiwan, 1996 to 2003. Can. J. Psychiatry 52, 28-36 (2007).
4. Hansen R, Gaynes B, Thieda P et al.: Meta-ana lysis of major depressive disorder relapse and recurrence with second-generation antidepressants. Psychiatr. Serv. 59, 1121-1130 (2008).
5. Zobel A, Maier W: Pharmacogenetics of antidepressive treatment. Eur. Arch. Psychiatry Clin. Neurosci. 260(5), 407-417 (2010).
6. Laje G, McMahon FJ: The pharmacogenetics of major depression: past, present, and future. Biol. Psychiatry 62, 1205-1207 (2007).
7. Pae CU, Patkar AA: Paroxetine: current status in psychiatry. Expert Rev. Neurother. 7, 107-120 (2007).
8. Jornil J, Jensen KG, Larsen F, Linnet K: Identifcation of cytochrome p450 isoforms involved in the metabolism of paroxetine and estimation of their importance for human paroxetine metabolism using a population-based simulator. Drug Metab. Dispos. 38, 376-385 (2010).
9. Kaye CM, Haddock RE, Langley PF et al.: A review of the metabolism and pharmacokinetics of paroxetine in man. Acta Psychiatr. Scand. Suppl. 350, 60-75 (1989).
10. Gardiner SJ, Begg EJ: Pharmacogenetics, drug-metabolizing enzymes, and clinical practice. Pharmacol. Rev. 58, 521-590 (2006).
11. Kristoffersen L, Bugge A, Lundanes E, Slordal L: Simultaneous determination of citalopram, fuoxetine, paroxetine and their metabolites in plasma and whole blood by high-performance liquid chromatography with ultraviolet and fuorescence detection. J. Chromatogr. 734, 229-246 (1999).
12. Haddock RE, Johnson AM, Langley PF et al.: Metabolic pathway of paroxetine in animals and man and the comparative pharmacological properties of its metabolites. Acta Psychiatr. Scand. Suppl. 350, 24-26 (1989).
13. Tang SW, Helmeste D: Paroxetine. Expert opin. Pharmacother. 9, 787-794 (2008).
14. Andersohn F, Willich SN: Interaction of serotonin reuptake inhibitors with tamoxifen. BMJ 340, c783 (2010).
15. Hori H, Yoshimura R, Ueda N, Ikenouchi-Sugita A, Umene-Nakano W, Nakamura J: A case with occurring adverse effects when cross-over titration from fuvoxamine to paroxetine associated with increasing the plasma fuvoxamine level in major depressive disorder. World J. Biol. Psychiatry 10, 620-622 (2009).
16. Ereshefsky L, Jhee S, Grothe D: Antidepressant drug-drug interaction profle update. Drugs R D 6, 323-336 (2005).
17. Laika B, Leucht S, Heres S, Schneider H, Steimer W: Pharmacogenetics and olanzapine treatment: CYP1A2*1F and serotonergic polymorphisms infuence therapeutic outcome. Pharmacogenomics J. 10, 20-29 (2010).
18. Demonstrates that the role of CYP1A2*1F infuences olanzapine concentration. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders DSM-IV-TR, The Fourth Edition (Text-Revised). American Psychiatric Publisher, Washington, DC, USA (2000).
19. Hamilton M: Development of a rating scale for primary depressive illness. Br. J. Soc. Clin. Psychol. 6, 278-296 (1967).
20. Uhr M, Tontsch A, Namendorf C et al.: Polymorphisms in the drug transporter gene ABCB1 predict antidepressant treatment response in depression. Neuron 57, 203-209 (2008).
21. Hamilton M: A rating scale for depression. J. Neurol. Neurosurg. Psychiatr. 23, 56-62 (1960).
22. Guy W: ECDEU Assessment Manual for Psychopharmacology: Publication No. ADM 76-338 (Revised Edition). National Institute of Health, Psychopharmacology Research Branch Publishers, MD, USA, 76-338 (1976).
23. Yu YW, Tsai SJ, Chen TJ, Lin CH, Hong CJ: Association study of the serotonin transporter promoter polymorphism and symptomatology and antidepressant response in major depressive disorders. Mol. Psychiatry 7, 1115-1119 (2002).
24. Ventura J, Liberman RP, Green MF, Shaner A, Mintz J: Training and quality assurance with the Structured Clinical Interview for DSM-IV (SCID-I/P). Psychiatry Res. 79, 163-173 (1998).
25. Muller MJ, Dragicevic A: Standardized rater training for the Hamilton Depression Rating Scale (HAMD-17) in psychiatric novices. J. Affect. Disord. 77, 65-69 (2003).
26. Cohen J: Weighted K: nominal scale agreement with provision for scaled disagreement or partial credit. Psychol. Bull. 70, 213-220 (1968).
27. Cohen J: A coeffcient of agreement for nominal scales. Educ. Psychol. Meas. 20, 37-46 (1960).
28. McGahuey CA, Gelenberg AJ, Laukes CA et al.: The Arizona Sexual Experience Scale (ASEX): reliability and validity. J. Sex Marital Ther. 26, 25-40 (2000).
29. Tiwari AK, Souza RP, Muller DJ: Pharmacogenetics of anxiolytic drugs.J. Neural. Transm. 116, 667-677 (2009).
30. Ingelman-Sundberg M, Sim SC, Gomez A, Rodriguez-Antona C: Infuence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects. Pharmacol. Ther. 116, 496-526 (2007).
31. Yuan HY, Chiou JJ, Tseng WH et al.: FASTSNP: an always up-to-date and extendable service for SNP function ana lysis and prioritization. Nucleic Acids Res. 34, W635-W641 (2006).
32. Barrett JC, Fry B, Maller J, Daly MJ: Haploview: ana lysis and visualization of LD and haplotype maps. Bioinformatics 21, 263-265 (2005).
33. Riedel M, Moller HJ, Obermeier M et al.: Response and remission criteria in major depression - a validation of current practice. J. Psychiatr. Res. 44(15), 1063-1068 (2010).
34. Gabriel SB, Schaffner SF, Nguyen H et al.: The structure of haplotype blocks in the human genome. Science 296, 2225-2229 (2002).
35. Rasmussen BB, Brosen K: Is therapeutic drug monitoring a case for optimizing clinical outcome and avoiding interactions of the selective serotonin reuptake inhibitors- Ther. Drug Monit. 22, 143-154 (2000).
36. Serretti A, Calati R, Massat I et al.: Cytochrome P450 CYP1A2, CYP2C9, CYP2C19 and CYP2D6 genes are not associated with response and remission in a sample of depressive patients. Int. Clin. Psychopharmacol. 24, 250-256 (2009).
37. Sachse C, Brockmoller J, Bauer S, Roots I: Functional signifcance of a C->A polymorphism in intron 1 of the cytochrome P450 CYP1A2 gene tested with caffeine. Br. J. Clin. Pharmacol. 47, 445-449 (1999).
38. Basile VS, Ozdemir V, Masellis M et al.: A functional polymorphism of the cytochrome P450 1A2 (CYP1A2) gene: association with tardive dyskinesia in schizophrenia. Mol. Psychiatry 5, 410-417 (2000).
39. Tsai MH, Lin KM, Hsiao MC et al.: Genetic polymorphisms of cytochrome P450 enzymes infuence metabolism of the antidepressant escitalopram and treatment response. Pharmacogenomics 11, 537-546 (2010).
40. Takeuchi DT, Chung RC, Lin KM et al.: Lifetime and twelve-month prevalence rates of major depressive episodes and dysthymia among Chinese Americans in Los Angeles. Am. J. Psychiatry 155, 1407-1414 (1998).